Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
Community
/
Switzerland
/
Pharmaceuticals & Biotech
Create a narrative
Lonza Group Community
SWX:LONN Community
1
Narratives
written by author
0
Comments
on narratives written by author
22
Fair Values set
on narratives written by author
Create a narrative
Lonza Group
Popular
Undervalued
Overvalued
Community Investing Ideas
Lonza Group
AN
AnalystConsensusTarget
Consensus Narrative from 22 Analysts
CDMO Focus And Vacaville Acquisition To Drive Operational Improvements By 2025
Key Takeaways Focus on CDMO business and Vacaville acquisition to drive revenue growth and boost sales. Strategic CHI exit and investment in growth to enhance margins and earnings.
View narrative
CHF 656.71
FV
17.7% undervalued
intrinsic discount
13.42%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
20
users have followed this narrative
6 days ago
author updated this narrative
Your Valuation for
LONN
LONN
Lonza Group
Your Fair Value
CHF
Current Price
CHF 540.60
32.0% undervalued
intrinsic discount
Growth estimate over
Annual revenue growth rate
5 Years
time period
%/yr
Decrease
Increase
Past
Future
0
12b
2015
2018
2021
2024
2025
2027
2030
Revenue CHF 11.5b
Earnings CHF 1.1b
Advanced
Set Fair Value